ATE533787T1 - Hepatozytenwachstumsfaktor (hgf)-bindende proteine - Google Patents

Hepatozytenwachstumsfaktor (hgf)-bindende proteine

Info

Publication number
ATE533787T1
ATE533787T1 AT07795607T AT07795607T ATE533787T1 AT E533787 T1 ATE533787 T1 AT E533787T1 AT 07795607 T AT07795607 T AT 07795607T AT 07795607 T AT07795607 T AT 07795607T AT E533787 T1 ATE533787 T1 AT E533787T1
Authority
AT
Austria
Prior art keywords
hgf
growth factor
binding proteins
hepatocyte growth
hepatocyte
Prior art date
Application number
AT07795607T
Other languages
German (de)
English (en)
Inventor
May Han
Kirk S Wright
William M Winston
Lyne Breault
Jie Lin
Bijan Etemad-Gilbertson
Christine Knuehl
Jeno Gyuris
Original Assignee
Aveo Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aveo Pharmaceuticals Inc filed Critical Aveo Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE533787T1 publication Critical patent/ATE533787T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT07795607T 2006-06-02 2007-06-01 Hepatozytenwachstumsfaktor (hgf)-bindende proteine ATE533787T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81071406P 2006-06-02 2006-06-02
US86046106P 2006-11-21 2006-11-21
PCT/US2007/012950 WO2007143098A2 (en) 2006-06-02 2007-06-01 Hepatocyte growth factor (hgf) binding proteins

Publications (1)

Publication Number Publication Date
ATE533787T1 true ATE533787T1 (de) 2011-12-15

Family

ID=38802082

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07795607T ATE533787T1 (de) 2006-06-02 2007-06-01 Hepatozytenwachstumsfaktor (hgf)-bindende proteine

Country Status (15)

Country Link
US (5) US7659378B2 (enExample)
EP (2) EP2380908A1 (enExample)
JP (2) JP4560582B2 (enExample)
KR (1) KR101196184B1 (enExample)
AR (1) AR061170A1 (enExample)
AT (1) ATE533787T1 (enExample)
AU (1) AU2007254853B2 (enExample)
BR (1) BRPI0712223A2 (enExample)
CA (1) CA2654019A1 (enExample)
ES (1) ES2378097T3 (enExample)
IL (2) IL195038A0 (enExample)
MX (1) MX2008015138A (enExample)
NO (1) NO20085422L (enExample)
NZ (1) NZ573819A (enExample)
WO (1) WO2007143098A2 (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7659378B2 (en) * 2006-06-02 2010-02-09 Aveo Pharmaceuticals, Inc. Hepatocyte growth factor (HGF) binding antibody
CA2654025C (en) * 2006-06-02 2016-08-02 Xoma Technology Ltd. Hepatocyte growth factor (hgf) binding proteins
HUE027154T2 (en) 2007-07-02 2016-08-29 Oncomed Pharm Inc Preparations and procedures for the treatment and diagnosis of cancer
US20090123946A1 (en) * 2007-10-19 2009-05-14 Abbott Laboratories Immunoassays and kits for the detection of ngal
US20090124022A1 (en) * 2007-10-19 2009-05-14 Abbott Laboratories Antibodies that bind to mammalian ngal and uses thereof
US8846036B2 (en) * 2007-10-19 2014-09-30 Abbott Laboratories Antibodies that bind to mammalian NGAL and uses thereof
AU2009241589B2 (en) * 2008-04-29 2013-10-10 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
US20100260668A1 (en) * 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
CA2725873C (en) 2008-05-29 2018-05-01 Galaxy Biotech, Llc Monoclonal antibodies to basic fibroblast growth factor
EP2297208A4 (en) 2008-06-03 2012-07-11 Abbott Lab DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND ITS USES
NZ589434A (en) * 2008-06-03 2012-11-30 Abbott Lab Dual variable domain immunoglobulins and uses thereof
US8187601B2 (en) * 2008-07-01 2012-05-29 Aveo Pharmaceuticals, Inc. Fibroblast growth factor receptor 3 (FGFR3) binding proteins
MX2010014574A (es) 2008-07-08 2011-04-27 Abbott Lab Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas.
HUE028589T2 (en) * 2008-07-10 2016-12-28 Toray Industries Pharmaceutical preparation for the treatment and prevention of cancer
US8101723B2 (en) 2008-11-07 2012-01-24 Galaxy Biotech, Llc Monoclonal antibodies to fibroblast growth factor receptor 2
JP2012508563A (ja) * 2008-11-12 2012-04-12 シェーリング コーポレイション 抗ＩＧＦ１Ｒ発現の増強のためのβＧｌ−ＩＧＧイントロン
WO2010119991A2 (en) 2009-04-17 2010-10-21 Takeda Pharmaceutical Company Limited Novel method of treating cancer
TW201109438A (en) * 2009-07-29 2011-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
BR112012004710A2 (pt) * 2009-09-01 2016-08-16 Abbott Lab imunoglobulinas de domínio variável duplo e uso das mesmas
PH12012500691A1 (en) 2009-10-15 2012-11-12 Abbott Lab Dual variable domain immunoglobulins and uses thereof
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
WO2012003338A1 (en) 2010-07-01 2012-01-05 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
AR082461A1 (es) 2010-08-03 2012-12-12 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
MX2013002270A (es) 2010-08-26 2013-05-14 Abbvie Inc Inmonoglubinas de dominio variable doble y usos de las mismas.
US20130236467A1 (en) 2010-11-24 2013-09-12 Jeremy Griggs Multispecific antigen binding proteins targeting hgf
EP2731625B1 (en) 2011-07-15 2018-04-18 OncoMed Pharmaceuticals, Inc. Rspo binding agents and uses thereof
WO2013078223A1 (en) * 2011-11-23 2013-05-30 Children's Hospital & Research Center Oakland Anti-factor h binding protein antibodies and methods of use thereof
UY34558A (es) 2011-12-30 2013-07-31 Abbvie Inc Proteínas de unión específicas duales dirigidas contra il-13 y/o il-17
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
AU2013289990B2 (en) 2012-07-13 2018-06-14 Oncomed Pharmaceuticals, Inc. RSPO3 binding agents and uses thereof
CA2890263C (en) 2012-11-01 2020-03-10 Abbvie Inc. Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof
US9481725B2 (en) 2013-03-14 2016-11-01 Alderbio Holdings, Llc Antibodies to HGF and compositions containing
EP2964673A4 (en) * 2013-03-14 2017-02-22 Alder Biopharmaceuticals, Inc. Antibodies to hgf and compositions containing
JP2016522793A (ja) 2013-03-15 2016-08-04 アッヴィ・インコーポレイテッド ＩＬ−１βおよび／またはＩＬ−１７に対して指向された二重特異的結合タンパク質
WO2015031578A1 (en) * 2013-08-28 2015-03-05 Abbvie Inc. Hgf assay
RU2016141385A (ru) 2014-03-24 2018-04-28 Дженентек, Инк. Лечение рака антагонистами с-мет и их корреляция с экспрессией hgf
EP3180027A4 (en) * 2014-08-15 2018-01-10 Oncomed Pharmaceuticals, Inc. Rspo1 binding agents and uses thereof
JP2017528523A (ja) 2014-09-16 2017-09-28 オンコメッド ファーマシューティカルズ インコーポレイテッド 線維性疾患の治療
ES2822228T3 (es) * 2014-10-24 2021-04-29 Univ Leland Stanford Junior Composiciones y métodos para inducir la fagocitosis de células positivas de clase I de CMH y contrarrestar la resistencia a anti-CD47/SIRPA
US10550187B2 (en) 2014-10-24 2020-02-04 Incept, Llc Extra luminal scaffold
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
WO2016205566A1 (en) * 2015-06-16 2016-12-22 The Regents Of The University Of California Fzd7 specific antibodies and vaccines to treat cancer and control stem cell function
JP7366388B2 (ja) 2016-03-28 2023-10-23 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 抗Ｒｙｋ抗体およびその使用方法
NL2017267B1 (en) * 2016-07-29 2018-02-01 Aduro Biotech Holdings Europe B V Anti-pd-1 antibodies
EP3634486A4 (en) 2017-06-05 2021-03-31 Janssen Biotech, Inc. GENETICALLY PRODUCED MULTISPECIFIC ANTIBODIES AND OTHER MULTIMERIC PROTEINS WITH ASYMMETRIC MUTATIONS OF THE CH2-CH3 REGION
WO2018232188A1 (en) * 2017-06-15 2018-12-20 Memorial Sloan Kettering Cancer Center Anti-l1-cam antibodies and uses thereof
IL319835A (en) 2017-12-06 2025-05-01 Avidity Biosciences Inc Compositions and methods for treating muscular dystrophy and myotonic dystrophy
US11155638B2 (en) 2018-05-08 2021-10-26 Rhode Island Hospital Anti-CHI3L1 antibodies for the detection and/or treatment of nonalcoholic fattly liver disease/nonalcoholic steatonhepatitis and subsequent complications
CA3133633A1 (en) * 2019-03-20 2020-09-24 Javelin Oncology, Inc. Anti-adam12 antibodies and chimeric antigen receptors, and compositions and methods comprising
CA3148713A1 (en) 2019-08-12 2021-02-18 Interna Technologies B.V. New treatments involving mirna-193a
US20230136088A1 (en) 2020-02-28 2023-05-04 Interna Technologies B.V. miRNA-193a for Promoting Immunogenic Cell Death
MX2022011880A (es) 2020-03-27 2022-10-20 Avidity Biosciences Inc Composiciones y metodos para tratar distrofia muscular.

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US6893625B1 (en) 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DE3856559T2 (de) 1987-05-21 2004-04-29 Micromet Ag Multifunktionelle Proteine mit vorbestimmter Zielsetzung
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
EP0571613B1 (en) 1991-12-13 2003-09-17 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
EP1514934B1 (en) 1992-02-06 2008-12-31 Novartis Vaccines and Diagnostics, Inc. Biosynthetic binding protein for cancer marker
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6066718A (en) 1992-09-25 2000-05-23 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
US6498144B1 (en) 1993-10-18 2002-12-24 North Shore - Long Island Jewish Research Institute Use of scatter factor to enhance angiogenesis
US5837676A (en) 1993-10-18 1998-11-17 Long Island Jewish Medical Center Use of scatter factor to enhance angiogenesis
US5707624A (en) 1994-06-03 1998-01-13 The Regents Of The University Of Michigan Treatment of Kaposi's sarcoma by inhibition of scatter factor
DE69738539T2 (de) 1996-12-03 2009-03-26 Amgen Fremont Inc. Vollkommen humane Antikörper die EGFR binden
US6872518B2 (en) 1997-09-22 2005-03-29 University Of Rochester Methods for selecting polynucleotides encoding T cell epitopes
US7459536B1 (en) 1999-11-09 2008-12-02 The United States Of America As Represented By The Secretary, Department Of Health And Human Services HGF-SF monoclonal antibody combinations
CN1671416B (zh) 2001-07-12 2013-01-02 杰斐逊·富特 超人源化抗体
US7220410B2 (en) 2003-04-18 2007-05-22 Galaxy Biotech, Llc Monoclonal antibodies to hepatocyte growth factor
US20040208876A1 (en) 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
US8609090B2 (en) 2003-07-18 2013-12-17 Amgen Inc. Specific binding agents to hepatocyte growth factor
KR100556660B1 (ko) 2003-11-11 2006-03-10 국립암센터 Ｈｇｆ의 중화가능 에피토프 및 이에 결합하는 중화 항체
KR20080026562A (ko) 2005-06-02 2008-03-25 갤럭시 바이오테크, 엘엘씨 항체를 이용한 뇌종양 치료 방법
AR059922A1 (es) 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
US7659378B2 (en) * 2006-06-02 2010-02-09 Aveo Pharmaceuticals, Inc. Hepatocyte growth factor (HGF) binding antibody
CA2654025C (en) 2006-06-02 2016-08-02 Xoma Technology Ltd. Hepatocyte growth factor (hgf) binding proteins
KR100829972B1 (ko) 2006-07-14 2008-05-16 재단법인서울대학교산학협력재단 항-ｈｇｆ/ｓｆ 인간화 항체 및 이의 제조방법

Also Published As

Publication number Publication date
US20110236377A1 (en) 2011-09-29
WO2007143098A2 (en) 2007-12-13
AU2007254853A2 (en) 2009-02-12
HK1129394A1 (en) 2009-11-27
US7935502B2 (en) 2011-05-03
US20100173361A1 (en) 2010-07-08
US7659378B2 (en) 2010-02-09
AU2007254853B2 (en) 2011-11-17
WO2007143098A3 (en) 2008-06-12
KR101196184B1 (ko) 2012-11-01
AU2007254853A1 (en) 2007-12-13
EP2029627A2 (en) 2009-03-04
JP5528246B2 (ja) 2014-06-25
WO2007143098A8 (en) 2009-01-08
JP4560582B2 (ja) 2010-10-13
NZ573819A (en) 2011-09-30
IL195038A0 (en) 2011-08-01
KR20090026315A (ko) 2009-03-12
IL219655A0 (en) 2012-06-28
BRPI0712223A2 (pt) 2012-07-10
EP2380908A1 (en) 2011-10-26
US8575318B2 (en) 2013-11-05
JP2010246565A (ja) 2010-11-04
EP2029627B1 (en) 2011-11-16
US8268315B2 (en) 2012-09-18
US20130203970A1 (en) 2013-08-08
NO20085422L (no) 2009-02-27
AR061170A1 (es) 2008-08-06
US20080038257A1 (en) 2008-02-14
US20140178934A1 (en) 2014-06-26
JP2009539348A (ja) 2009-11-19
ES2378097T3 (es) 2012-04-04
MX2008015138A (es) 2009-01-28
CA2654019A1 (en) 2007-12-13

Similar Documents

Publication Publication Date Title
ATE533787T1 (de) Hepatozytenwachstumsfaktor (hgf)-bindende proteine
DK2027156T3 (da) Hepatocytvækstfaktor (HGF)bindingsprotein
NO20082564L (no) Hepatosyttvekstfaktorintronfusjonsproteiner
BRPI0716762A2 (pt) melhorias da cultura celular
DK2046826T3 (da) Exendin-fusionsproteiner
ATE484264T1 (de) Beleuchtete infusionskanüle
ATE552336T1 (de) Herstellung biologisch aktiver proteine
DK3118221T3 (da) Proteiner
EP2037982A4 (en) CONTINUOUS CATHETER WITH ANTICOAGULANT FEATURES
ATE509627T1 (de) Zusammensetzungen mit nebivolol
EP2172198A4 (en) P27 PROTEIN INDUKTOR
DK1733707T3 (da) Infusionskanylesystem
DE602007001492D1 (de) Schubkraftkorrektur
EP1784219A4 (en) STABILIZING FORMULATIONS
DK2600655T3 (da) Systeminformationsopdateringer i LTE
DE602005002689D1 (de) Luftbefeuchter
FI20041704A0 (fi) Stabiilit mikrobisiirrosteet ja menetelmät niiden valmistamiseksi
DK1927646T3 (da) Odoriseringsmiddel med forbedret stabilitet
DE602006015573D1 (de) Bipolarplatte
ITGE20050091A1 (it) Incubatrice
DE112006001343A5 (de) Patientenauflage
ATE497973T1 (de) Rekombinante produktion heparinbindender proteine
ZA200809483B (en) Hepatocyte growth factor (HGF) binding proteins
EP1931379A4 (en) IMPROVED SOLUBILITY PROTEINS AND METHODS FOR THE PRODUCTION AND USE OF SAID PROTEINS
EP1951337A4 (en) EXTRACORPORAL BLOOD CLEANSING